Our Mission at Artiva

  • Efficacy. efficacy
  • Safety. safety
  • Accessibility. access

NK Cell Therapies for Autoimmune Disease and Cancer

We are an immunotherapy company capable of producing off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers.

Artiva’s CEO, Fred Aslan, M.D., was featured on BiotechTV to discuss advancing AlloNK in clinical trials for autoimmune diseases.

Efficacy. Efficacy. NK cells can be combined with other therapies (such as monoclonal antibodies or innate cell engagers) to increase antibody-dependent cellular cytotoxicity (ADCC) and resulting clinical efficacy. Further, NK cells can be engineered to potentially increase the targeting and activity of the therapy.

Safety. Unlike approved CAR-T therapy, NK cells can be used in an allogeneic, mismatched setting without inducing graft versus host disease (GvHD), enabling the treatment of many patients from the same donor cells. NK cells have not been shown to induce s evere cytokine release syndrome or neurotoxicity, which are risks associated with CAR-T cell treatment.

Accessibility. Our cell therapy manufacturing platform yields consistent and highly active NK cells that are cryopreserved and ready for off-the-shelf therapeutic use. Our end-to-end process is developed to achieve our goal of cost-effectiveness and to ensure broad patient access.


We are supported by leading life science investors and our corporate partner, who bring experience in developing, scaling, manufacturing, and commercializing transformative therapies.